ELDN Eledon Pharmaceuticals Inc
Price (delayed)
$3.31
Market cap
$198.21M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.75
Enterprise value
$178.61M
Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring
Highlights
Eledon Pharmaceuticals's EPS has surged by 84% YoY and by 57% QoQ
The net income has soared by 69% YoY and by 18% from the previous quarter
The quick ratio has surged by 93% since the previous quarter but it has declined by 8% year-on-year
The debt has surged by 149% year-on-year and by 90% since the previous quarter
Key stats
What are the main financial stats of ELDN
Market
Valuations
Earnings
Shares outstanding
59.88M
Market cap
$198.21M
Enterprise value
$178.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.67
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$70.58M
Net income
-$36.18M
EBIT
-$35.75M
EBITDA
-$35.39M
Free cash flow
-$47.27M
Per share
Balance sheet
Liquidity
EPS
-$0.75
EPS diluted
-$0.75
Free cash flow per share
-$0.97
Book value per share
$1.98
Revenue per share
$0
TBVPS
$3.65
Total assets
$177.41M
Total liabilities
$59.27M
Debt
$954,000
Equity
$118.14M
Working capital
$132.15M
Debt to equity
0.01
Current ratio
12.42
Quick ratio
12.11
Net debt/EBITDA
0.55
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-29.3%
Return on equity
-84.7%
Return on invested capital
-35.5%
Return on capital employed
-21.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ELDN stock price
How has the Eledon Pharmaceuticals stock price performed over time
Intraday
2.8%
1 week
-1.78%
1 month
-20.24%
1 year
71.5%
YTD
-19.66%
QTD
-2.36%
Financial performance
How have Eledon Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$70.58M
Net income
-$36.18M
Gross margin
N/A
Net margin
N/A
The net income has soared by 69% YoY and by 18% from the previous quarter
The operating income has dropped by 64% year-on-year and by 26% since the previous quarter
Growth
What is Eledon Pharmaceuticals's growth rate over time
Valuation
What is Eledon Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.67
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Eledon Pharmaceuticals's EPS has surged by 84% YoY and by 57% QoQ
The stock's price to book (P/B) is 81% more than its 5-year quarterly average of 0.9
The company's equity has surged by 55% QoQ
Efficiency
How efficient is Eledon Pharmaceuticals business performance
The return on invested capital has surged by 80% year-on-year and by 32% since the previous quarter
ELDN's return on assets has surged by 76% year-on-year and by 33% since the previous quarter
Eledon Pharmaceuticals's return on equity has surged by 71% QoQ and by 50% YoY
Dividends
What is ELDN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ELDN.
Financial health
How did Eledon Pharmaceuticals financials performed over time
The total assets is 199% more than the total liabilities
The total assets has soared by 99% YoY and by 55% from the previous quarter
The quick ratio has surged by 93% since the previous quarter but it has declined by 8% year-on-year
The debt is 99% smaller than the equity
The debt has surged by 149% year-on-year and by 90% since the previous quarter
The company's debt to equity has shrunk by 80% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.